(Q45024357)

English

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) st

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) st (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

François Guilhot

object named as

François Guilhot

13

0 references

Hagop Kantarjian

9

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

object named as

Timothy P Hughes

11

0 references

Michele Baccarani

1

object named as

Michele Baccarani

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Jorge Eduardo Cortes

12

object named as

Jorge E Cortes

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Jerald P Radich

10

object named as

Jerald P Radich

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

3

object named as

Susan Branford

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

7

object named as

Manisha Mone

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

author name string

Dong-Wook Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Fabrizio Pane

5

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Lidia Mongay

6

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Christine-Elke Ortmann

8

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

publication date

1 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

99

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

616-624

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

https://scigraph.springernature.com/pub.10.1007/s12185-014-1566-2

0 references

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1566-2

21 January 2018

Identifiers

10.1007/S12185-014-1566-2

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Dimensions Publication ID

0 references

release_42fkvj3s5bfu7jr4lqh6dryew4

1 reference

https://api.fatcat.wiki/v0/release/42fkvj3s5bfu7jr4lqh6dryew4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45024357&oldid=2062684381"